Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study

Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study

Abstract Diffuse large B-cell lymphoma (DLBCL), either concurrent with or transformed from follicular lymphoma (FL) is often excluded from clinical trials. Lenalidomide has response rates of 45% in relapsed transformed DLBCL. Herein we present an analysis of MC078E, a phase II clinical trial testing...

Full description

Bibliographic Details
Main Authors: Sanjal H. Desai, Betsy LaPlant, William R. Macon, Rebecca L. King, Yucai Wang, David J. Inwards, Ivana Micallef, Patrick B. Johnston, Luis F. Porrata, Stephen M. Ansell, Thomas M. Habermann, Thomas E. Witzig, Grzegorz S. Nowakowski
Format: Article
Language:English
Published: Nature Publishing Group 2021-09-01
Series:Blood Cancer Journal
Online Access:https://doi.org/10.1038/s41408-021-00542-z

Internet

https://doi.org/10.1038/s41408-021-00542-z

Similar Items